<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23507" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Inflammatory Arthritis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Poudel</surname>
            <given-names>Pooja</given-names>
          </name>
          <aff>Suny Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lappin</surname>
            <given-names>Sarah L.</given-names>
          </name>
          <aff>Upstate University Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pooja Poudel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Lappin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23507.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Inflammatory arthritis includes a group of arthritis accompanied by joint pain, swelling, warmth, and tenderness in the joints, and morning stiffness that lasts for an hour. Because most of the inflammatory forms of arthritis are systemic, symptoms related to inflammation may occur in other parts of the body, including skin rashes, eye inflammation, hair loss, dry mouth, and fever. The increased number of cells and inflammatory substances within the joint can irritate it, in turn, wearing down the cartilage and swelling of the synovium. This activity reviews the etiology, presentation, evaluation, and management of inflammatory arthritis and reviews the role of the interprofessional team in evaluating, diagnosing, and managing the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the various forms of inflammatory arthritis.</p></list-item><list-item><p>Outline the components of a proper evaluation and assessment of a patient presenting with inflammatory arthritis, including any indicated imaging studies.</p></list-item><list-item><p>Summarize the treatment options available for the various forms of inflammatory arthritis.</p></list-item><list-item><p>Explain the importance of interprofessional team strategies for improving care coordination and communication to aid in prompt diagnosis of the various inflammatory arthritides and improving outcomes in patients diagnosed with the condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23507&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23507">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23507.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Arthritis is defined as "painful inflammation and stiffness of the joints." Arthritis can be broadly classified into two categories, inflammatory arthritis and non-inflammatory arthritis. Differentiating whether arthritis in a patient is inflammatory or non-inflammatory is the crucial first step towards further diagnosing and managing the patient. Inflammatory arthritis is usually associated with the classic symptoms of inflammation - dolor (pain), rubor (erythema), calor (warmth), tumor (swelling), and&#x000a0;functio laesa (loss of function), although all the features may not always be present. Inflammatory arthritis can be due to several etiologies, including infectious and non-infectious, and may or may not be associated with systemic features of the underlying condition causing inflammatory arthritis. If left untreated, inflammatory arthritis invariably leads to joint damage and deformities.<xref ref-type="bibr" rid="article-23507.r1">[1]</xref><xref ref-type="bibr" rid="article-23507.r2">[2]</xref></p>
      </sec>
      <sec id="article-23507.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Etiologies of inflammatory arthritis include:</p>
        <p><bold>Infectious or septic arthritis:&#x000a0;</bold>Organisms causing infectious arthritis include&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>,&#x000a0;<italic toggle="yes">Streptococcal pneumoniae</italic>,&#x000a0;<italic toggle="yes">Neisseria gonorrhea</italic>, anaerobic bacteria, mycobacteria species, brucellosis,&#x000a0;<italic toggle="yes">Borrelia burgdorferi</italic>, sporotrichosis, coccidioidomycosis, viruses (<italic toggle="yes">Parvovirus</italic>,&#x000a0;<italic toggle="yes">Enterovirus</italic>, and&#x000a0;<italic toggle="yes">Rubella</italic>).&#x000a0;Septic arthritis is usually monomicrobial. Polymicrobial infections are usually less common and occur in the setting of penetrating trauma involving joint space. Septic arthritis due to gram-negative bacteria is usually observed in the setting of trauma or intravenous drug abuse.<xref ref-type="bibr" rid="article-23507.r3">[3]</xref><xref ref-type="bibr" rid="article-23507.r4">[4]</xref></p>
        <p><bold>Crystalline arthritis:</bold> Crystal-induced arthritis includes gout, pseudogout, and basic calcium phosphate (BCP) disease. Hyperuricemia leading to deposition of monosodium urate crystals in the joint space causes gout. Hyperuricemia is a predisposing factor of gout, although 80% of the hyperuricemic individuals never develop gout. Hyperuricemia can be caused by primary or secondary overproduction or underexcretion of uric acid, an end product of purine metabolism. Pseudogout is caused by synovial inflammation caused by deposited calcium pyrophosphate crystals in the cartilage.&#x000a0;Most of the cases of calcium pyrophosphate&#x000a0;deposition (CPPD) are idiopathic, but&#x000a0;disorders of calcium, phosphorus, or magnesium metabolism,&#x000a0;familial chondrocalcinosis, and hemochromatosis can be associated with the illness. Basic calcium phosphate disease is rare and can be seen in association with hypothyroidism and diabetes mellitus.&#x000a0;</p>
        <p><bold>Autoimmune inflammatory arthritis:</bold> This is a broad category that can be further divided into several categories:</p>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatoid arthritis - seropositive or seronegative.</p>
          </list-item>
          <list-item>
            <p>Juvenile idiopathic arthritis.</p>
          </list-item>
          <list-item>
            <p>Seronegative spondyloarthritis - This family of HLA-B27 associated arthropathies includes psoriatic arthritis, ankylosing spondylitis, reactive arthritis, arthritis associated with inflammatory bowel disease, and non-radiographic spondyloarthritis.<xref ref-type="bibr" rid="article-23507.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>SAPHO syndrome -&#x000a0;synovitis, acne, pustulosis, hyperostosis, and osteitis.</p>
          </list-item>
          <list-item>
            <p>Arthritis associated with underlying connective tissue or autoimmune diseases - arthritis is a common clinical manifestation of several rheumatic and autoimmune diseases such as:
<list list-type="bullet"><list-item><p>Systemic lupus erythematosus</p></list-item><list-item><p>Drug-induced lupus</p></list-item><list-item><p>Sjogren syndrome</p></list-item><list-item><p>Mixed connective tissue disease</p></list-item><list-item><p>Systemic sclerosis</p></list-item><list-item><p>Inflammatory myopathies</p></list-item><list-item><p>Behcet's disease</p></list-item><list-item><p>Vasculitis: Henoch Schnolein Purpura, ANCA-associated vasculitis</p></list-item><list-item><p>Sarcoidosis</p></list-item><list-item><p>Relapsing polychondritis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Arthritis associated with malignancy - Inflammatory arthritis can be a frequent paraneoplastic phenomenon associated with underlying malignancies.&#x000a0;
<list list-type="bullet"><list-item><p>Palmar fasciitis&#x000a0;and&#x000a0;polyarthritis&#x000a0;(PFPA) syndrome - frequently associated with ovarian cancer but can be seen in association with any malignancy.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23507.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The annual incidence of early inflammatory arthritis ranges from 115 to 271 per 100,000 adults, and the incidence of undifferentiated inflammatory arthritis (UA) ranges from 41 to 149 per 100,000 adults. Out of which, 13% to 54% of patients with undifferentiated inflammatory arthritis will develop rheumatoid arthritis (RA), and in 21% to 87%, undifferentiated inflammatory arthritis will persist&#x000a0;as such. A specific diagnosis can be made at the presentation in about 70% of such patients, the most common being rheumatoid arthritis.<xref ref-type="bibr" rid="article-23507.r6">[6]</xref><xref ref-type="bibr" rid="article-23507.r7">[7]</xref><xref ref-type="bibr" rid="article-23507.r8">[8]</xref>&#x000a0;Gout is the most common inflammatory arthritis, while rheumatoid arthritis is the most common autoimmune inflammatory arthritis.&#x000a0; While females are more likely than males to have most autoimmune inflammatory arthritis such as rheumatoid arthritis, systemic lupus erythematosus, and Sjogren syndrome, gout and seronegative spondyloarthritis are more common in males than in females.&#x000a0; Age of onset is variable, juvenile idiopathic arthritis usually presenting before 10 years of age, most autoimmune inflammatory arthropathies presenting in the early adulthood while late age of onset is not uncommon in autoimmune inflammatory arthropathies and paraneoplastic inflammatory arthritis.</p>
      </sec>
      <sec id="article-23507.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pathophysiology is distinct and different based on the underlying etiology of inflammatory arthritis.&#x000a0; External or self-antigen leading to an immune-mediated inflammatory response by&#x000a0;an influx of inflammatory cells such as neutrophils, lymphocytes, and macrophages from the bloodstream into the synovial membrane and is associated with hyperplasia of synovial fibroblasts. In some cases, damage to the cartilage and bone can cause joint destruction. Direct invasion of the joint by an infectious organism resulting in the inflammation of the synovium is usually the underlying pathogenesis for most infectious arthritis.&#x000a0; Further, infectious agents such as hepatitis B, hepatitis C, parvovirus B19 may trigger an immune response leading to the onset of inflammatory arthritis.<xref ref-type="bibr" rid="article-23507.r9">[9]</xref><xref ref-type="bibr" rid="article-23507.r10">[10]</xref><xref ref-type="bibr" rid="article-23507.r11">[11]</xref>&#x000a0;In autoimmune inflammatory arthropathies, an interplay of environmental and genetic factors leads to activation of the immune system leading to inflammatory arthritis.&#x000a0; In crystalline arthropathies, the occurrence of crystals in the synovium acts as an antigen leading to a neutrophil-mediated inflammatory cascade.</p>
      </sec>
      <sec id="article-23507.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>While there is a significant overlap, most inflammatory arthropathies can be classified based on history and physical examination. The onset of symptoms is usually acute in infectious and crystalline arthropathies while subacute or insidious in most autoimmune inflammatory arthropathies. Infectious arthritis is usually monoarticular. Crystalline arthropathies can be monoarticular, oligoarticular, or polyarticular.&#x000a0; While most autoimmune inflammatory arthropathies are polyarticular, they may initially have an oligoarticular or a monoarticular presentation gradually evolving into a polyarticular pattern. Bacterial infectious arthritis is more common in previously damaged joints and lower extremities such as knees. Inflammatory arthritis in Lyme disease usually presents as acute onset monoarticular inflammation of the knee.&#x000a0;</p>
        <p>Inflammatory arthritis secondary to viruses such as hepatitis B, hepatitis C, parvovirus B19 is usually polyarticular and may mimic rheumatoid arthritis. 50% of gout patients present with podagra, which is acute onset inflammatory arthritis of the 1st metatarsophalangeal joint in the foot. The 1st metatarsophalangeal joint is eventually involved in 90% of the patients with gout. Pseudogout is more common in the knees, wrists, and 2nd and 3rd metacarpophalangeal joints of the hands. Basic calcium phosphate disease more commonly involves the shoulders.&#x000a0;Rheumatoid arthritis typically involves small joints of the upper and lower extremities but spares the spine (except C1-C2) and distal interphalangeal joints in the hands.&#x000a0; Patients with seronegative spondyloarthropathies may have axial involvement and peripheral inflammatory arthritis, these patients as a&#x000a0;predilection for lower extremity joints. Enthesitis and dactylitis may be seen frequently in seronegative spondyloarthropathies.&#x000a0; Patients with inflammatory arthritis associated with other connective tissue diseases such as systemic lupus erythematosus usually have other systemic clinical features such as skin rashes in systemic lupus erythematosus, sclerodactyly in systemic sclerosis, keratoconjunctivitis sicca in Sjogren syndrome, etc.<xref ref-type="bibr" rid="article-23507.r12">[12]</xref>&#x000a0;</p>
        <p>Thus, knowledge about the onset of arthritis, number of joints involved, symmetry of involvement, distribution of involvement, and pattern of involvement can give clues about the potential underlying etiology of inflammatory arthritis in a patient.</p>
      </sec>
      <sec id="article-23507.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratories</bold>
</p>
        <p>Elevation in inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein are frequently seen in all inflammatory arthropathies. Thrombocytosis and anemia of chronic disease can be frequently seen. Leukocytosis usually accompanies infectious arthritis, while leukopenia might be a feature of infectious arthritis associated with underlying autoimmune diseases such as systemic lupus erythematosus. Renal function may be abnormal in patients with gout who are more likely to have associated chronic kidney disease. Hyperuricemia is frequently seen in patients with gout, although serum uric acid levels may be falsely low during an acute episode of gout. Patients with pseudogout secondary to underlying metabolic diseases such as hypercalcemia, hyperparathyroidism, hypomagnesemia, and hemochromatosis may have laboratory abnormalities associated with the underlying disorder. Specific serological workup should be pursued when autoimmune inflammatory arthritis is in the differential.&#x000a0; Patients with rheumatoid arthritis frequently have positive rheumatoid factor and/or anti-cyclic&#x000a0;citrullinated peptide antibodies. Patients with underlying connective tissue diseases such as systemic lupus erythematosus, Sjogren syndrome, mixed connective tissue disease, inflammatory myopathies, and systemic sclerosis may have associated autoantibodies such as antinuclear antibody and more specific autoantibodies such as&#x000a0;anti-double-stranded DNA antibody, anti-Smith antibody, anti-Ro antibody, Anti-La antibody, etc.&#x000a0;</p>
        <p>
<bold>Synovial Fluid Analysis</bold>
</p>
        <p>Aspiration of the synovial fluid and detailed analysis is critical in the evaluation of inflammatory arthritis. Synovial fluid shall be analyzed for total cell counts and differential, polarized light microscopy, Gram stain and cultures, and fungal/AFB cultures when appropriate. Total cell counts are usually less than 2000 cells/mm3 in non-inflammatory arthritis and more than 5000 cells/mm^3 in inflammatory arthritis. A total cell count of more than&#x000a0;50,000 cells/mm^3 cells and/or more than 90% neutrophils have a strongly positive likelihood ratio of being associated with septic arthritis, although it can&#x000a0;present in acute gout or pseudogout as well. Septic arthritis and crystalline arthropathies usually have neutrophilic predominance, while rheumatoid arthritis usually has lymphocytic predominance in the synovial fluid.&#x000a0; Monosodium urate crystals on polarized light microscopy are needle-shaped and strongly negatively birefringent. Calcium pyrophosphate crystals on polarized light microscopy or rhomboid-shaped and weakly positively birefringent. Basic calcium phosphate crystals are not visible on polarized light microscopy and need special staining for visualization.</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Plain radiographs may be initially normal in early inflammatory arthritis or may show periarticular osteopenia. As the disease progresses, periarticular erosions can be seen in inflammatory arthritis such as rheumatoid arthritis.<xref ref-type="bibr" rid="article-23507.r1">[1]</xref><xref ref-type="bibr" rid="article-23507.r13">[13]</xref><xref ref-type="bibr" rid="article-23507.r14">[14]</xref>&#x000a0;In comparison, gout erosions tend to be juxta-articular/rat-bite erosions with overhanging edges. Chondrocalcinosis or CPPD deposition can be easily visualized on plain radiographs.&#x000a0;Entheseal calcifications can be seen in seronegative spondyloarthritis. Radiographs in early axial spondyloarthropathies are normal but can show bamboo spine and sacroiliac joint fusion and erosions later in the disease process.&#x000a0;MRI can be a beneficial tool, especially if radiographs are nondiagnostic. MRI&#x000a0;is more&#x000a0;sensitive than&#x000a0;plain film in evaluating&#x000a0;synovitis, erosions, sacroiliitis, with a much higher sensitivity than X-rays. CT scan is usually not helpful in evaluating inflammatory arthropathies but can be used to detect chondrocalcinosis or bony erosions when not evident on plain radiographs. Musculoskeletal ultrasound is an extremely useful&#x000a0;tool in&#x000a0;evaluating peripheral inflammatory arthritis and can help&#x000a0;assess the presence of synovitis, degree of synovitis, presence of erosions or chondrocalcinosis, and can be used to perform ultrasound-guided diagnostic aspirations. Nuclear medicine joint scan is usually not the preferred modality due to its high sensitivity but very poor specificity but can be used to evaluate the presence or absence of inflammation and to evaluate prosthetic joint infections.</p>
      </sec>
      <sec id="article-23507.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Inflammation is generally&#x000a0;reversible, while joint destruction is not. Early and appropriate&#x000a0;treatment may prevent disease persistence/progression, joint damage, and disability.</p>
        <p>Prompt diagnosis and treatment of septic arthritis are of utmost importance as untreated septic arthritis or delay in treatment invariably leads to permanent joint destruction and other complications such as sepsis. After the synovial fluid analysis is performed, intravenous antibiotics with broad coverage should be initiated, which can later be targeted based on sensitivity analysis from the synovial fluid analysis. Joint lavage and orthopedic evaluation may be necessary in some cases. Prosthetic joint infections can be difficult to manage. Removing hardware followed by a spacer and a long course of antibiotics before repeat surgery to replace the hardware is usually indicated in prosthetic joint infections.</p>
        <p>Gout and pseudogout can mimic septic arthritis. In patients with acute monoarthritis, once septic arthritis has been ruled out by synovial fluid analysis, and the diagnosis of gout or pseudogout has been confirmed by synovial fluid analysis, treatment with anti-inflammatory agents such as oral, systemic or intra-articular corticosteroids, NSAIDs, or colchicine shall be pursued. The choice of agent depends on the severity of inflammatory arthritis as well as patient comorbidities.<xref ref-type="bibr" rid="article-23507.r15">[15]</xref>&#x000a0;In patients with recurrent acute attacks of gout, or patients with gout who have chronic kidney disease, tophi, or erosions, treatment with urate-lowering therapy shall be considered as well.</p>
        <p>In patients with autoimmune inflammatory arthritis, early treatment to suppress inflammation and prevent recurrent inflammation, disease progression, and joint damage are crucial. The choice of treatment depends on the underlying etiology. Conventional disease-modifying antirheumatic drugs such as methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine are usually first-line agents, and if lack of response, treatment with biologic disease-modifying antirheumatic drugs shall be pursued as appropriate.<xref ref-type="bibr" rid="article-23507.r16">[16]</xref>&#x000a0;Close monitoring with baseline and serial laboratories is indicated in patients being treated with disease-modifying antirheumatic drugs.&#x000a0;The initial therapeutic goal is to achieve significant clinical improvement within 3 months, which may be defined as at least a 50% reduction in disease activity.<xref ref-type="bibr" rid="article-23507.r7">[7]</xref><xref ref-type="bibr" rid="article-23507.r17">[17]</xref><xref ref-type="bibr" rid="article-23507.r18">[18]</xref>&#x000a0;Combination therapies of conventional disease-modifying antirheumatic drugs with other conventional or biologic disease-modifying antirheumatic drugs are more effective and often needed to control the disease. Combination therapies of biologic disease-modifying antirheumatic drugs are not recommended due to the increased risk of infections.&#x000a0;Long-term use of corticosteroids is usually not recommended, especially at moderate to high doses due to concerns&#x000a0;regarding adverse effects. The role of corticosteroids in managing chronic autoimmune inflammatory arthritis should ideally be limited in managing flares with has needed corticosteroid dose-tapers.</p>
        <p>Surgery is rarely needed in the early stages of inflammatory arthritis but can be considered in patients with chronic deformities due to underlying chronic autoimmune inflammatory arthropathies such as rheumatoid arthritis. An interprofessional team approach, including patient education, physical and occupational therapy, diet, and lifestyle modification, can significantly improve patient outcomes.</p>
      </sec>
      <sec id="article-23507.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>It is of importance to differentiate inflammatory from noninflammatory arthritis. The most common form of non-inflammatory arthritis is osteoarthritis which usually has an insidious onset and gradually worsens. Typical joints involved in primary osteoarthritis include the knees, hips, lumbar spine, 1st metatarsophalangeal joints in the feet, proximal and distal interphalangeal joints in the hands, and 1st carpometacarpal joint in the wrist. Repetitive use or injuries can lead to the involvement of other joints as well, such as the shoulders, elbows, ankles, and wrists. It can be symmetric or non-symmetric. Bony hypertrophy changes can be palpable on the exam, especially in the hands and feet. The joint can be tender and swollen, but erythema or warmth is usually absent. Synovial fluid analysis reveals noninflammatory fluid. Radiographs can show characteristic osteoarthritic changes with loss of joint space and osteophytes. Erosions are rare, but central "gull-wing" erosions can be seen in erosive osteoarthritis of the hands involving the proximal and distal interphalangeal joints.</p>
      </sec>
      <sec id="article-23507.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis depends on the cause of arthritis. If treated early and appropriately, acute inflammatory arthropathies such as septic arthritis or crystal-induced arthritis have an excellent prognosis. Delay in treatment or misdiagnosis can lead to erosions and permanent joint damage, which can be aggressive, especially in septic arthritis. In patients with rheumatoid arthritis or seronegative spondyloarthritis, early and aggressive treatment can prevent long-term complications such as erosions and joint deformities. The prognosis of inflammatory arthritis associated with underlying connective tissue disorders depends on the underlying disorder.<xref ref-type="bibr" rid="article-23507.r19">[19]</xref></p>
      </sec>
      <sec id="article-23507.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications in septic arthritis arise from delay in treatment or mass diagnosis, possibly leading to aggressive and permanent joint damage. Chronic gout, rheumatoid arthritis, and seronegative spondyloarthritis can be associated with erosive changes and joint damage, which can interfere with daily function.</p>
      </sec>
      <sec id="article-23507.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with crystalline arthropathies such as gout&#x000a0;require education regarding diet and lifestyle modification which can help manage gout. Patients with chronic inflammatory arthropathies frequently need long-term immunosuppressive medications. They&#x000a0;need counseling about the potential benefits and adverse effects of these medications and the necessity for regular monitoring laboratory workups. Finally, they should also&#x000a0;understand the importance of regular exercises.</p>
      </sec>
      <sec id="article-23507.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team approach is indicated for best outcomes in patients with inflammatory arthritis. In patients with septic arthritis, multi-specialty evaluation with internal medicine, orthopedics, rheumatology, and infectious&#x000a0;diseases may be needed. For patients with other autoimmune inflammatory arthropathies, close communication between the rheumatologist and primary care provider is of utmost importance. Further, pharmacists can assist in patient education about medications, and the nursing team can assist in ensuring patient compliance. Physical therapy and occupational therapy frequently play a key role in helping the patients maintain the full range of the function of the joints and encouraging them to exercise and lose weight. [Level 5]</p>
      </sec>
      <sec id="article-23507.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23507&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23507">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/inflammatory-arthritis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23507">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23507/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23507">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23507.s15">
        <title>References</title>
        <ref id="article-23507.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krenn</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Waldstein</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Najm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gaulke</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Histopathological classification principles of rheumatic joint diseases : Contribution of pathology to the diagnosis].</article-title>
            <source>Orthopade</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>11</issue>
            <fpage>941</fpage>
            <page-range>941-948</page-range>
            <pub-id pub-id-type="pmid">30255358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bucher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koyfman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Emergent Complications of Rheumatoid Arthritis.</article-title>
            <source>J Emerg Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>55</volume>
            <issue>5</issue>
            <fpage>647</fpage>
            <page-range>647-658</page-range>
            <pub-id pub-id-type="pmid">30253957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x00142;odzi&#x00144;ski</surname>
                <given-names>&#x00141;</given-names>
              </name>
              <name>
                <surname>Wis&#x00142;owska</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comorbidities in rheumatic arthritis.</article-title>
            <source>Reumatologia</source>
            <year>2018</year>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>228</fpage>
            <page-range>228-233</page-range>
            <pub-id pub-id-type="pmid">30237627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Exercise for Athletes With Inflammatory Arthritis.</article-title>
            <source>Curr Sports Med Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>302</fpage>
            <page-range>302-307</page-range>
            <pub-id pub-id-type="pmid">30204634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Premkumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morse</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levack</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bostrom</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Periprosthetic Joint Infection in Patients with Inflammatory Joint Disease: Prevention and Diagnosis.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <day>10</day>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>68</fpage>
            <pub-id pub-id-type="pmid">30203376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sewerin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brinks</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haase</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vordenb&#x000e4;umen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and incidence of psoriasis and psoriatic arthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>286</fpage>
            <page-range>286-287</page-range>
            <pub-id pub-id-type="pmid">30242033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holroyd</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Seth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bukhari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malaviya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Litwic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Topliffe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ledingham</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>372</fpage>
            <pub-id pub-id-type="pmid">30239912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuncer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gilgil</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ka&#x000e7;ar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kurtai&#x0015f;</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kutlay</surname>
                <given-names>&#x0015e;</given-names>
              </name>
              <name>
                <surname>B&#x000fc;t&#x000fc;n</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yal&#x000e7;in</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Akarirmak</surname>
                <given-names>&#x000dc;</given-names>
              </name>
              <name>
                <surname>Altan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ardi&#x000e7;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ardi&#x000e7;o&#x0011f;lu</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Altay</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cant&#x000fc;rk</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cerraho&#x0011f;lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>&#x000c7;evik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Durmaz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dursun</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Duru&#x000f6;z</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Erdo&#x0011f;an</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Evcik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>G&#x000fc;rsoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hizmetli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaptano&#x0011f;lu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kayhan</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Kirnap</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kokino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kozano&#x0011f;lu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kuran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>&#x000d6;ncel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sindel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Orkun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarpel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sava&#x0015f;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x0015e;endur</surname>
                <given-names>&#x000d6;F</given-names>
              </name>
              <name>
                <surname>&#x0015e;enel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>U&#x0011f;urlu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uzunca</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tekeo&#x0011f;lu</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>Guillemin</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Rheumatoid Arthritis and Spondyloarthritis in Turkey: A Nationwide Study.</article-title>
            <source>Arch Rheumatol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-136</page-range>
            <pub-id pub-id-type="pmid">30207568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyoshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Collagen-Induced Arthritis Models.</article-title>
            <source>Methods Mol Biol</source>
            <year>2018</year>
            <volume>1868</volume>
            <fpage>3</fpage>
            <page-range>3-7</page-range>
            <pub-id pub-id-type="pmid">30244448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sk&#x00142;adanowska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Savvides</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Adamopoulos</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.</article-title>
            <source>Clin Immunol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>206</volume>
            <fpage>15</fpage>
            <page-range>15-22</page-range>
            <pub-id pub-id-type="pmid">30196070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruiz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Margolles</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role of gut microbiota in lupus: what we know in 2018?</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>787</fpage>
            <page-range>787-792</page-range>
            <pub-id pub-id-type="pmid">30173572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Senthelal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ardeshirzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <chapter-title>Arthritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30085534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakker</surname>
                <given-names>PAC</given-names>
              </name>
              <name>
                <surname>Ramiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ez-Zaitouni</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>van Lunteren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramonda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Oosterhout</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reijnierse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Gaalen</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-391</page-range>
            <pub-id pub-id-type="pmid">30203929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ventura-R&#x000ed;os</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Faugier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barzola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De la Cruz-Becerra</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Bringas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-D&#x000ed;az</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Reliability of ultrasonography to detect inflammatory lesions and structural damage in juvenile idiopathic arthritis.</article-title>
            <source>Pediatr Rheumatol Online J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>17</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <pub-id pub-id-type="pmid">30223838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abeles</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Libbey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mount</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Danve</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lenert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehra</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>TSK</given-names>
              </name>
              <name>
                <surname>Toprover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2020 American College of Rheumatology Guideline for the Management of Gout.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>744</fpage>
            <page-range>744-760</page-range>
            <pub-id pub-id-type="pmid">32391934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Benjamin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lappin</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <chapter-title>Disease-Modifying Antirheumatic Drugs (DMARD)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29939640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duru&#x000f6;z</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>&#x000dc;nal</surname>
                <given-names>&#x000c7;</given-names>
              </name>
              <name>
                <surname>Ulutatar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sanal Toprak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nd&#x000fc;z</surname>
                <given-names>OH</given-names>
              </name>
            </person-group>
            <article-title>The Validity and Reliability of Turkish Version of the Jenkins Sleep Evaluation Scale in Rheumatoid Arthritis.</article-title>
            <source>Arch Rheumatol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-167</page-range>
            <pub-id pub-id-type="pmid">30207571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerbini</surname>
                <given-names>CAF</given-names>
              </name>
              <name>
                <surname>Abud-Mendoza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mendez-Patarroyo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Angelo Andrade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vlahos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Borlenghi</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Maintenance of low disease activity and remission with etanercept-disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis: Subset analysis of a randomized trial.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>36</issue>
            <fpage>e11989</fpage>
            <pub-id pub-id-type="pmid">30200078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23507.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prieto-Alhambra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>VY</given-names>
              </name>
              <name>
                <surname>Walker-Bone</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Silman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mamas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blackburn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dent</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Protheroe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilkie</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Estimating the population health burden of musculoskeletal conditions using primary care electronic health records.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2021</year>
            <month>Oct</month>
            <day>02</day>
            <volume>60</volume>
            <issue>10</issue>
            <fpage>4832</fpage>
            <page-range>4832-4843</page-range>
            <pub-id pub-id-type="pmid">33560340</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
